Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCell InstituteTSE:7096 -0.40%69 Return-on-Tangible-Equity is 5.84% as of Mar. 2026, which is 36% below its 10-year median of 9.10. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,816.44 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,199 Biotechnology companies, StemCell Institute ranks better than 83.07% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. StemCell Institute's annualized net income for the quarter that ended in Mar. 2026 was 円142 Mil. StemCell Institute's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円2,434 Mil. Therefore, StemCell Institute's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 5.84%.
The historical rank and industry rank for StemCell Institute's Return-on-Tangible-Equity or its related term are showing as below:
TSE:7096'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.88 Med: 9.1 Max: 24.92
Current: 6.35
During the past 9 years, StemCell Institute's highest Return-on-Tangible-Equity was 24.92%. The lowest was 4.88%. And the median was 9.10%.
TSE:7096's Return-on-Tangible-Equity is ranked better than 83.07% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs TSE:7096: 6.35
StemCell Institute (TSE:7096) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
StemCell Institute Return-on-Tangible-Equity Related Terms
StemCell Institute Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for StemCell Institute's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCell Institute Return-on-Tangible-Equity Chart
TSE:7096 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, StemCell Institute's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where StemCell Institute's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.84% mean?
StemCell Institute (TSE:7096) has a Return-on-Tangible-Equity of 5.84% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on StemCell Institute and its competitors. This is 36% below median its historical median of 9.10. Over the past decade, StemCell Institute's Return-on-Tangible-Equity has ranged from 4.88 to 24.92. According to the industry distribution chart, StemCell Institute ranks #203 out of 1199 companies in the Biotechnology industry, placing it in the top 16.9%.
Is StemCell Institute's Return-on-Tangible-Equity too high?
StemCell Institute's current Return-on-Tangible-Equity of 5.84% is 36% below median its 10-year median of 9.10. Over the past 10 years, this metric has ranged from a low of 4.88 to a high of 24.92. Based on the distribution chart, StemCell Institute ranks #203 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #203 out of 1199 companies for Return-on-Tangible-Equity. This places StemCell Institute in the top 17% of its industry — outperforming the majority of peers. Historically, StemCell Institute's own Return-on-Tangible-Equity has ranged from 4.88 to 24.92 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on StemCell Institute and its competitors. StemCell Institute's current Return-on-Tangible-Equity is 5.84%, which is 36% below median its own 10-year median of 9.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,816.44, compared to a current price of 円749.00 — trading 58.8% below its estimated fair value. The current Return-on-Tangible-Equity is 5.84%, which is 36% below median its 10-year median of 9.10. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Return-on-Tangible-Equity is 5.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円749.00 is trading 58.8% below its estimated GF Value™ of 円1,816.44.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
Return-on-Tangible-Equity: 5.84% (36% below median its 10-year median of 9.10)
GF Value™: 円1,816.44 vs. price of 円749.00 (58.8% below fair value)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
